22157.jpg
EU (European Union) Clinical Trial Regulation 536/2014 Overview and Implementation Training Course (February 23-24, 2023)
02 févr. 2023 11h28 HE | Research and Markets
Dublin, Feb. 02, 2023 (GLOBE NEWSWIRE) -- The "EU (European Union) Clinical Trial Regulation 536/2014: Overview and Implementation Training Course" conference has been added to ...
assisTek joins PA Biotech Center
assisTek Opens New Office Space in Pennsylvania Biotechnology Center
02 févr. 2023 09h00 HE | assisTek, Inc.
DOYLESTOWN, Pa., Feb. 02, 2023 (GLOBE NEWSWIRE) -- assisTek, a leader in innovative eClinical technology and eSource solutions for clinical research, is delighted to announce the opening of a new...
POINT logo light blue (png).png
POINT Biopharma to Participate in Upcoming Investor Conferences
02 févr. 2023 08h30 HE | POINT Biopharma
INDIANAPOLIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
22157.jpg
EU (European Union) Clinical Trial Regulation 536/2014: 2 Day Overview and Implementation Training Course (May 22-23, 2023)
01 févr. 2023 14h43 HE | Research and Markets
Dublin, Feb. 01, 2023 (GLOBE NEWSWIRE) -- The "EU (European Union) Clinical Trial Regulation 536/2014: Overview and Implementation Training Course" conference has been added to ...
1nHealth and The Mighty
1nHealth Partners With The Mighty to Bring Fresh Patient Centricity to Clinical Trial Recruitment
01 févr. 2023 10h30 HE | 1nHealth
ORLANDO, Fla., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Clinical trials bring hope to patients by exposing them to potentially groundbreaking therapies. Thus, it can be especially devastating for patients...
CITELINE_LOGO_FULL COLOUR_RGB.png
Citeline to Unveil Capabilities of New Clinical Trial Workflow Solution at SCOPE 2023 in Orlando 
31 janv. 2023 09h00 HE | Citeline
NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- At the Summit for Clinical Ops Executives (SCOPE) Feb. 6-9 in Orlando, Citeline will reveal details of its soon-to-be-released clinical feasibility...
22157.jpg
2023 Outlook on the VISTA Inhibitor Market: Featuring Curis, Epitomics, Hummingbird Bioscience, ImmuNext and Kineta Among Others
27 janv. 2023 08h03 HE | Research and Markets
Dublin, Jan. 27, 2023 (GLOBE NEWSWIRE) -- The "Global VISTA Inhibitor Clinical Trials & Market Opportunity Insight 2023" report has been added to ResearchAndMarkets.com's offering.Report...
22157.jpg
Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028: FDA and EMA Special Drug Designations to Ignite R&D Progress
27 janv. 2023 04h58 HE | Research and Markets
Dublin, Jan. 27, 2023 (GLOBE NEWSWIRE) -- The "Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The dysregulation of...
Academic Urology Research Investigators Consortium
Criterium, Inc. Announces Formation of New Oncology Research Consortium for Genito-Urinary Indications
26 janv. 2023 09h30 HE | Criterium Inc.
SARATOGA SPRINGS, N.Y., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Criterium, Inc., a full-service Contract Research Organization (CRO), is pleased to announce AURIC (Academic Urology Research Investigators...
Alterity.png
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
25 janv. 2023 07h25 HE | ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia AND SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...